CycloPharm (ASX:CYC): Interview with CEO James McBrayer

September 16, 2021

CYC, Cyclopharm

Summary

We spoke with James McBrayer, CEO of CycloPharm (ASX:CYC), one of Marc & Stuart’s Top Picks, about the work CYC is now doing to resubmit its application with the FDA for Technegas, as well as the significant opportunity that Cyclopharm is targeting beyond pumonary embolism.

 

Disclosure: Stocks Down Under staff and/or director(s) own CycloPharm shares.

 

Stocks Down Under
Investing has never been easier!

 

Get Marc & Stuart’s Top Picks

Improve your investment skills with our Investor Webinars

Learn about ASX-listed stocks with our 4 editions per week across all sectors

Get access to everything with a 30-day FREE TRIAL.

No credit card required!

 

GET A 30-DAY FREE TRIAL